News, views and contacts from the global Pharmaceutical industry
 

News Archive

Archive of industry news from the global pharmaceutical industry

News By Date

July 2014

Top

NICE recommends Sucampo’s Amitiza for chronic idiopathic constipation treatment
24 July 2014 The UK National Institute of Health and Care Excellence (NICE) has recommended Sucampo Pharmaceuticals' Amitiza (lubiprostone) as a treatment option for chronic idiopathic constipation (CIC)...

Neurotrope and Mount Sinai collaborate to develop Bryostatin-1 for NPC disease
24 July 2014 Neurotrope Bioscience has entered into a collaboration agreement with Icahn School of Medicine at Mount Sinai to develop Bryostatin-1 in the treatment of Niemann-Pick Type C (NPC) disease....

UK researchers to gain access to deprioritised pharmaceutical compounds
23 July 2014 UK Business Secretary Vince Cable has announced a new partnership between the Medical Research Council (MRC) and seven global pharmaceutical companies, which will give researchers access to...

Sage Therapeutics receives fast track designation for status epilepticus therapy
23 July 2014 Ligand Pharmaceuticals has announced that its partner Sage Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for the Captisol-enabled SAGE-547 to...

Aduro’s pancreatic cancer immunotherapy gets FDA breakthrough therapy designation
22 July 2014 The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Aduro BioTech's pancreatic cancer combination treatment that consists of its CRS-207 and GVAX...

Shire acquisition could save AbbVie $8bn tax on Humira over 15 years, says GlobalData
22 July 2014 AbbVie's relocation to Ireland following the acquisition of Shire for $54bn is expected to reduce the annual tax expense for the company by more than 7%, according to research and consulting...

Salix Pharmaceuticals and Pharming receive FDA approval for Ruconest
21 July 2014 Salix Pharmaceuticals and Pharming have announced US Food and Drug Administration (FDA) approval of Ruconest for treatment of acute angioedema attacks in adult and adolescent patients...

CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin's lymphoma therapy
21 July 2014 CTI BioPharma has obtained Israeli Ministry of Health's approval for Pixuvri (pixantrone), as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive...

Pfizer to acquire InnoPharma for $360m
18 July 2014 Pfizer has entered into an agreement to acquire US-based pharmaceutical development company InnoPharma for...

FDA Grants breakthough therapy designation for InterMune’s pirfenidone
18 July 2014 InterMune has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its pirfenidone, an investigational treatment for adult patients with idiopathic...

FDA approves Octapharma’s immune thrombocytopenic purpura therapy
17 July 2014 The US Food and Drug Administration (FDA) has approved Octapharma USA's Octagam 10% for treatment of adults with chronic immune thrombocytopenic purpura (ITP), a platelet disorder that can...

Medical Research Council to lead initiative to tackle antimicrobial resistance
17 July 2014 The UK Medical Research Council (MRC) will lead a cross-council initiative to tackle antimicrobial resistance (AMR) in all...

Boehringer Ingelheim launches anti-DVT drug Pradaxa in UK
16 July 2014 Boehringer Ingelheim’s anti-deep vein thrombosis (DVT) and pulmonary embolism (PE) drug Pradaxa is now available in the UK following European Medicines Agency (EMA)...

FDA grants priority review for Genentech’s cervical cancer therapy
16 July 2014 The US Food and Drug Administration (FDA) has accepted Roche subsidiary Genentech's supplemental biologics licence application (sBLA) and granted priority review for Avastin plus chemotherapy...

Mylan to acquire non-US developed markets specialty and assets from Abbott
15 July 2014 Mylan has entered into a definitive agreement to acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction of...

Health Canada approves Sunovion’s Aptiom to treat partial-onset seizures in epilepsy patients
15 July 2014 Health Canada has approved Sunovion Pharmaceuticals Canada's Aptiom, a voltage-gated sodium channel inhibitor, for use as a once-daily adjunctive therapy for treatment of partial-onset seizures...

ProStrakan to acquire Archimedes Pharma for £230m
14 July 2014 Kyowa Hakko Kirin subsidiary ProStrakan has entered into an agreement with Denmark-based Novo to acquire the entire share capital of Archimedes Pharma for a consideration of £230m in...

Zafgen’s Prader-Willi syndrome therapy receives orphan drug designation in Europe
14 July 2014 The European Commission (EC) has granted orphan drug designation to US-based Zafgen for its beloranib for treating Prader-Willi...

FDA accepts Kythera’s ATX-101 new drug application
11 July 2014 Kythera Biopharmaceuticals' new drug application (NDA) for its ATX-101, a submental contouring injectable drug, has been accepted for filing by the US Food and Drug Administration...

Baxter announces acquisition of AesRx
11 July 2014 Baxter International has announced the acquisition of US biopharmaceutical company AesRx, including development and commercialisation of AesRx’s investigational sickle cell disease treatment...

Iroko files new drug application for Zorvolex in Lebanon
10 July 2014 US-based Iroko Pharmaceuticals has announced the filing of a new drug application for Zorvolex, a nonsteroidal anti-inflammatory drug, with the Republic of Lebanon Ministry of Public Health...


cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1243308781_ap1243308781_1857678299_874850511